Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

Hims & Hers (HIMS) stock is nosediving after Novo Nordisk (NVO) ended its deal with the company over continued sales of ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Novo Nordisk A/S (NVO) ...

Among them, WW International (WW), formerly known as WeightWatchers, hit a rough patch earlier this year, resulting in WW ...

Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

A once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a ...

Shares climbed approximately 2.4–2.7%, touching highs between $163.93 (£120.58) and $164.37 (£120.90) before pulling back to ...

The ASX fell 0.11pc in trade, with 7 of 11 sectors lower. The resources industry was a silver lining; both gold and iron ore ...